Advaxis Inc. (Nasdaq: ADXS) entered a $40 million global development and commercialization agreement with Amgen for the immunotherapy treatment ADXS-NEO sending the stock price soaring $2.61 to close at $11.08.
Advaxis enters development agreement
August 02, 2016 at 17:10 PM EDT
